相关实验视频

Updated: Jul 21, 2025

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
07:18

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia

Published on: November 9, 2018

8.4K

针对阿尔茨海默病的抗胺单克隆抗体疗法:神经病学的新兴问题

Vijay K Ramanan1, Melissa J Armstrong1, Parichita Choudhury1

  • 1From the Department of Neurology (V.K.R., L.K.J.), Mayo Clinic, Rochester, MN; Department of Neurology (M.J.A.), University of Florida College of Medicine; Norman Fixel Institute for Neurologic Diseases (M.J.A.), University of Florida, Gainesville; Cleo Roberts Center (P.C.), Banner Sun Health Research Institute, Sun City, AZ; Rocky Mountain Neurology (K.C.), Lone Tree, CO; Department of Neurology (R.H.H., D.A.W.), Department of Physical Medicine and Rehabilitation (R.H.H.), and Department of Psychiatry (R.H.H.), University of Pennsylvania Perelman School of Medicine, Philadelphia; Abington Neurological Associates (B.C.K.), Ltd., Abington, PA; and American Academy of Neurology (S.R.W.), Minneapolis, MN.

Neurology
|July 26, 2023
PubMed
概括

针对粉样蛋白的新阿尔茨海默病 (AD) 治疗方法提供了希望,但需要大幅改变实践. 神经科医生需要调整工作流程,以便有效和公平地使用这些疾病修饰单克隆抗体 (mAbs).

更多相关视频

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps10:19

Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps

Published on: August 14, 2016

9.3K
Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

8.8K

相关概念视频

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
524
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.6K
Amyloid Fibrils03:03

Amyloid Fibrils

Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K